The weight-loss injection boom has just met the regulator. South Africa's health-products authority, SAHPRA, has ordered an urgent recall of every semaglutide and tirzepatide product compounded by iDexis, a Pretoria pharmacy trading as Sentra. Those are the same active drugs behind blockbuster brands like Ozempic, Wegovy and Mounjaro.
Why the recall is so serious
This is a Class I, Type A recall, the most serious category, meaning the products are treated as a real risk to patients. On 8 July, SAHPRA joined the Pharmacy Council and the health professions council in warning that any doctor or pharmacist who keeps prescribing or dispensing the jabs faces disciplinary action under the Medicines and Related Substances Act. The trouble came to light during a May inspection, which found the pharmacy was not really compounding medicines for individual patients at all, but mass-producing unregistered jabs for the open market; the authorities seized all the injectable products found on site.
What inspectors found
The list of problems is alarming. Inspectors flagged illegally imported active ingredients, no testing to confirm purity or strength, unsterile manufacturing rooms and no system to monitor side effects. SAHPRA says it has already linked adverse events, including hospitalisations, to the products. The recalled range runs across semaglutide pens in 0.5mg, 1mg and 2mg strengths and tirzepatide pens in 5mg, 10mg and 15mg, though the regulator warns the list is not exhaustive, as some batches were distributed before its inspection. The crackdown follows a court interdict won by Novo Nordisk, the maker of Ozempic, after the pharmacy was reportedly shifting about 85,000 copycat pens a month and outselling the real brands.
The bigger picture
SAHPRA chief executive Boitumelo Semete-Makokotlela said the authority would keep taking decisive action against anyone breaking the rules, because unregistered medicines pose a serious risk to public health. The Pharmacy Council added that pharmacists caught making or distributing the jabs risk severe penalties, including removal from the register. The uncomfortable takeaway is how easily a backyard operation outsold the pharmaceutical giants, a sign of just how hungry the weight-loss market has become. For anyone tempted by a cheaper shortcut, the message is blunt: the discount version could land you in hospital.
